20/20 Biolabs, Inc. reported a decline in revenue during the first quarter of 2026 as it advances commercialization of its OneTest diagnostic platforms aimed at early cancer detection and chronic disease risk assessment. The company operates an accredited lab offering AI-enhanced blood tests using protein biomarkers, positioning its solutions as affordable and accessible alternatives to ctDNA-based competitors. Although recent revenues remain limited and operating losses continue, management is focused on scaling sales, growing reimbursement pathways—particularly via firefighter screening programs—and leveraging its Clinical Laboratory Innovation Accelerator to support international diagnostics startups. Risks include sustained capital needs, regulatory uncertainties, and competitive pressures from better-funded peers.